NeoPhore: Driving neoantigen production via DNA mismatch repair
NeoPhore is making tumor cells more visible to the immune system by triggering neoantigen production
NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.
Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune system regards as non-self -- including T cell therapies and cancer vaccines that either target or deliver the newly formed antigens.
NeoPhore Ltd. wants to take a different tack by creating the neoantigens in the patient to make the tumors more visible to the immune